The association of Adiponectin polymorphism (rs2241766) with susceptibility and prognosis in Egyptian Hematological malignancies Patients: A case–control study

Abstract

Background: Haematological malignancies are ranked as the highest in incidence. Adiponectin (ADIPOQ), the most abundant circulating adipocytokine, plays a major role in the regulation of insulin sensitivity, metabolism, and hematopoiesis. Various ADIPOQ gene polymorphisms are associated with an increased risk of different cancers. However, to the best of our knowledge, the association between ADIPOQ T45G (rs2241766) single nucleotide polymorphism (SNP) and leukemia is unknown. Aim: This study aimed to investigate the association between ADIPOQ (rs2241766) and the clinicopathological status of Egyptian leukemia patients. Materials and Methods: A case-control design was used, including 80 leukemia patients and 70 healthy controls. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used for genotyping. Survival analysis and biochemical investigations including hematological and lipid profiles, liver and kidney functions in addition to anthropometric measurements were also determined. Results: A significant positive correlation between ADIPOQ gene T45G (rs2241766) SNP and leukemia incidence was detected. The G allele was more frequent in leukemia patients compared to the T allele. Kaplan-Meier analysis revealed that the SNP rs2241766was associated with the patient’s event-free survival but not the overall survival. In addition, G carriers, hyperglycemia, and hyperuricemia patients had a significantly shorter median EFS compared with T carriers, normoglycaemia, and normoglycemia patients. Conclusion: The current study shows an association between the SNP (rs2241766) and leukemia incidence and prognosis in Egyptian patients. Furthermore, an association between the rs2241766 and high prevalence of hyperglycemia and dyslipidemia in the G allele carrier’s leukemia patients was also evident.